🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 3 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 21/03/2006 | 37,95 | 40,23 | 37,85 | 37,95 | -5,57% | 6,27% | 1.569.500 |
| 20/03/2006 | 40,64 | 40,90 | 39,32 | 40,19 | -0,91% | 3,89% | 1.243.400 |
| 17/03/2006 | 39,69 | 40,59 | 39,21 | 40,56 | +2,71% | 3,48% | 2.011.500 |
| 16/03/2006 | 39,45 | 40,09 | 39,23 | 39,49 | +0,59% | 2,18% | 1.154.400 |
| 15/03/2006 | 37,63 | 39,47 | 37,51 | 39,26 | +4,83% | 5,21% | 1.831.800 |
| 14/03/2006 | 36,83 | 37,75 | 36,69 | 37,45 | +1,27% | 2,88% | 1.173.600 |
| 13/03/2006 | 37,08 | 37,72 | 36,87 | 36,98 | -0,59% | 2,29% | 1.373.300 |
| 10/03/2006 | 37,61 | 37,85 | 36,34 | 37,20 | -2,05% | 4,01% | 2.277.900 |
| 09/03/2006 | 36,95 | 38,13 | 36,69 | 37,98 | -5,71% | 3,90% | 4.648.200 |
| 08/03/2006 | 38,85 | 40,78 | 37,67 | 40,28 | +1,59% | 8,01% | 3.639.000 |
| 07/03/2006 | 43,38 | 43,38 | 39,59 | 39,65 | -8,68% | 8,74% | 2.912.800 |
| 06/03/2006 | 43,81 | 44,23 | 43,15 | 43,42 | -0,89% | 2,47% | 1.224.100 |
| 03/03/2006 | 44,00 | 44,35 | 43,63 | 43,81 | -0,41% | 1,64% | 1.407.800 |
| 02/03/2006 | 43,49 | 44,49 | 43,26 | 43,99 | -0,25% | 2,83% | 1.429.400 |
| 01/03/2006 | 43,33 | 44,30 | 41,75 | 44,10 | +1,99% | 5,89% | 1.972.800 |
| 28/02/2006 | 44,01 | 44,14 | 42,11 | 43,24 | -2,17% | 4,61% | 2.712.100 |
| 27/02/2006 | 43,45 | 44,71 | 43,01 | 44,20 | +2,31% | 3,91% | 2.196.800 |
| 24/02/2006 | 41,69 | 43,20 | 41,61 | 43,20 | +3,82% | 3,81% | 2.132.600 |
| 23/02/2006 | 38,50 | 42,34 | 38,50 | 41,61 | +7,69% | 9,97% | 4.268.400 |
| 22/02/2006 | 37,70 | 38,68 | 37,23 | 38,64 | +3,34% | 3,85% | 1.204.500 |
| 21/02/2006 | 37,70 | 37,98 | 36,21 | 37,39 | -0,90% | 4,69% | 1.522.900 |
| 17/02/2006 | 37,36 | 38,38 | 37,01 | 37,73 | +0,86% | 3,67% | 1.256.400 |
| 16/02/2006 | 36,89 | 37,50 | 36,60 | 37,41 | +1,88% | 2,44% | 941.500 |
| 15/02/2006 | 36,26 | 37,20 | 36,12 | 36,72 | +1,52% | 2,98% | 981.700 |
| 14/02/2006 | 34,63 | 36,49 | 34,55 | 36,17 | +4,87% | 5,60% | 1.449.400 |
| 13/02/2006 | 35,61 | 35,87 | 34,33 | 34,49 | -3,93% | 4,32% | 959.500 |
| 10/02/2006 | 36,19 | 36,42 | 34,65 | 35,90 | -1,40% | 4,89% | 1.540.100 |
| 09/02/2006 | 37,10 | 37,65 | 36,21 | 36,41 | -1,41% | 3,88% | 1.330.300 |
| 08/02/2006 | 35,96 | 36,93 | 35,86 | 36,93 | +2,27% | 2,98% | 1.971.700 |
| 07/02/2006 | 36,11 | 37,85 | 35,80 | 36,11 | +5,28% | 5,68% | 4.380.600 |